drugset / Trial / NCT01111318
Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this study is to assess the effect of mild, moderate and severe hepatic impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral administration of BI 10773 as a single dose.
Timeline
- Start
- 2010-07
- Primary completion
- 2010-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 50 mg | Oral |